Literature DB >> 3701388

Preoperative chemotherapy followed by surgery with possible postoperative radiotherapy in squamous cell carcinoma of the esophagus: evaluation of the chemotherapy component.

R W Carey, A D Hilgenberg, E W Wilkins, N C Choi, D J Mathisen, H Grillo.   

Abstract

Twenty-four patients with squamous cell cancer of the esophagus were entered into a treatment protocol consisting of preoperative chemotherapy (CT), surgical resection (SR), and possible postoperative CT or radiation therapy (RT) beginning August 1981. CT consisted of two cycles of 5-fluorouracil, 1,000 mg/m2, by continuous intravenous infusion for 4 days and cisplatin, 100 mg/m2, on day 4 with mannitol-induced diuresis at 4-week intervals. Postoperatively, RT was administered when resection margins were minimal or if paraesophageal nodes were abnormal; the RT consisted of 5,000 to 5,400 cGy to the tumor area plus a 800- to 1,200-cGy boost to known abnormal tumor margins. Nineteen of 24 patients were resectable (79%). There was one SR death (5%). One of 22 had a normal barium swallow post-CT, no visible tumor at SR, and no pathologic evidence of any residual disease. There was complete radiologic and gross clinical disappearance of tumor post-CT or post-SR in ten of 22 patients (45%). Four of 22 (18%) had greater than or equal to 50% regression, and five of 22 (23%) had no response. Toxicity of CT was mild. Eight of 19 patients (42%) received RT, and six of 19 (32%) received CT postoperatively. Sixteen of 24 (67%) are alive with a median duration of observation of 9.5 months. Eight of 24 (33%) are dead, five of whom had not responded to preoperative CT. Ten of 14 responders are alive and disease free. The mean survival time for nonresponders was 6.70 months and for responders, 20.40 months, with the longest survivor disease free at 45 months.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3701388     DOI: 10.1200/JCO.1986.4.5.697

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  5 in total

1.  [Preoperative chemotherapy in esophageal cancer: an advantage or danger for surgical intervention?].

Authors:  P Schlag; R Herrmann; U Raeth; B Lehner; V Schwarz; C Herfarth
Journal:  Langenbecks Arch Chir       Date:  1987

Review 2.  Adjuvant therapies for cancer of the thoracic esophagus.

Authors:  T Nishihira; T Nakano; S Mori
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

3.  First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up.

Authors:  E Ancona; A Ruol; C Castoro; V Chiarion-Sileni; S Merigliano; S Santi; L Bonavina; A Peracchia
Journal:  Ann Surg       Date:  1997-12       Impact factor: 12.969

Review 4.  Today's Mistakes and Tomorrow's Wisdom in the Surgical Treatment of Barrett's Adenocarcinoma.

Authors:  Giovanni Maria Garbarino; Mark Ivo van Berge Henegouwen; Suzanne Sarah Gisbertz; Wietse Jelle Eshuis
Journal:  Visc Med       Date:  2022-05-24

Review 5.  Cancer of the esophagus: the Wayne State University experience.

Authors:  L Leichman
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.